Literature DB >> 31865408

The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia.

Ian Alberts1, Christos Sachpekidis2, Lotte Dijkstra2, George Prenosil2, Eleni Gourni2, Silvan Boxler3, Tobias Gross3, George Thalmann3, Kambiz Rahbar4, Axel Rominger2, Ali Afshar-Oromieh2.   

Abstract

PURPOSE: Differentiating between prostate cancer (PC) lesions and benign structures which exhibit radiotracer uptake in PSMA-ligand PET/CT can be challenging. Additional late imaging has been shown to be a powerful method for the discrimination between PC and non-PC lesions, owing to the increasing tracer uptake of the former. Nevertheless, there are no pre-existing studies which describe the dynamic tracer uptake for ganglia, which this present study aims to address.
METHODS: Fifty consecutive patients with PC who received standard and late 68Ga-PSMA-11-PET/CT (by local protocol at 1.5 h "standard" and 2.5 h p.i. "late") underwent retrospective evaluation. All lesions with a tracer uptake above local background indicative for ganglia as well as PC lesions were analysed with regard to their maximum standardised uptake values (SUVmax) and localisation.
RESULTS: Overall, 86 PSMA-positive ganglia were identified in 70% (n = 35) of the patients. Five ganglia exhibited PSMA avidity at late imaging only, and three at standard imaging only. A total of 66 lesions suggestive for PC were detected in 44 patients (88%), of which 45% (n = 30) were morphologically identified as lymph nodes (LN), the remainder being locally recurrent lesions or bone metastases. No solid organ metastases were present in our cohort. At late scanning, 73% of the LN exhibited an increase in SUVmax, whereas 65% of the ganglia exhibited a decreasing or stable SUVmax.
CONCLUSION: Whereas the presence of increasing tracer uptake in potential PC lesions can provide additional data about the likelihood of malignancy, increasing SUVmax alone does not reliably differentiate between ganglia and PC lesions and is a potential diagnostic pitfall. We therefore recommend high-resolution CT to enable morphological characterisation of ganglia.

Entities:  

Keywords:  Ganglion; PET/CT; PSMA; Positron emission tomography; Prostate cancer; Prostate-specific membrane antigen

Mesh:

Substances:

Year:  2019        PMID: 31865408     DOI: 10.1007/s00259-019-04552-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  38 in total

1.  Positron flight in human tissues and its influence on PET image spatial resolution.

Authors:  Alejandro Sánchez-Crespo; Pedro Andreo; Stig A Larsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-10       Impact factor: 9.236

2.  The celiac ganglia: anatomic study using MRI in cadavers.

Authors:  Xiao Ming Zhang; Qiong Hui Zhao; Nan Lin Zeng; Chang Ping Cai; Xing Guo Xie; Cheng Jun Li; Jun Liu; Ji Yong Zhou
Journal:  AJR Am J Roentgenol       Date:  2006-06       Impact factor: 3.959

3.  The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer.

Authors:  Ali Afshar-Oromieh; Lars Peter Sattler; Walter Mier; Boris A Hadaschik; Jürgen Debus; Tim Holland-Letz; Klaus Kopka; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2017-01-06       Impact factor: 10.057

4.  Overview of prostate-specific membrane antigen.

Authors:  Sam S Chang
Journal:  Rev Urol       Date:  2004

5.  Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.

Authors:  Matthias Eiber; Tobias Maurer; Michael Souvatzoglou; Ambros J Beer; Alexander Ruffani; Bernhard Haller; Frank-Philipp Graner; Hubert Kübler; Uwe Haberkorn; Michael Eisenhut; Hans-Jürgen Wester; Jürgen E Gschwend; Markus Schwaiger
Journal:  J Nucl Med       Date:  2015-03-19       Impact factor: 10.057

6.  Improving the detection of small lesions using a state-of-the-art time-of-flight PET/CT system and small-voxel reconstructions.

Authors:  Daniëlle Koopman; Jorn A van Dalen; Martine C M Lagerweij; Hester Arkies; Jaep de Boer; Ad H J Oostdijk; Cornelis H Slump; Pieter L Jager
Journal:  J Nucl Med Technol       Date:  2015-01-22

7.  68Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging.

Authors:  Christoph Rischpler; Teresa I Beck; Shozo Okamoto; Anna M Schlitter; Karina Knorr; Markus Schwaiger; Jürgen Gschwend; Tobias Maurer; Philipp T Meyer; Matthias Eiber
Journal:  J Nucl Med       Date:  2018-01-25       Impact factor: 10.057

8.  68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer.

Authors:  Wolfgang P Fendler; Dorothea F Schmidt; Vera Wenter; Kolja M Thierfelder; Christian Zach; Christian Stief; Peter Bartenstein; Thomas Kirchner; Franz J Gildehaus; Christian Gratzke; Claudius Faber
Journal:  J Nucl Med       Date:  2016-06-03       Impact factor: 10.057

9.  Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.

Authors:  Ali Afshar-Oromieh; Christian M Zechmann; Anna Malcher; Matthias Eder; Michael Eisenhut; Heinz G Linhart; Tim Holland-Letz; Boris A Hadaschik; Frederik L Giesel; Jürgen Debus; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-27       Impact factor: 9.236

Review 10.  Current status of theranostics in prostate cancer.

Authors:  Irene Virgolini; Clemens Decristoforo; Alexander Haug; Stefano Fanti; Christian Uprimny
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-28       Impact factor: 9.236

View more
  13 in total

1.  Dual time point imaging of staging PSMA PET/CT quantification; spread and radiomic analyses.

Authors:  Ayşegül Aksu; Özge Vural Topuz; Gülşah Yılmaz; Gamze Çapa Kaya; Burçak Yılmaz
Journal:  Ann Nucl Med       Date:  2022-01-06       Impact factor: 2.668

2.  Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer.

Authors:  Yizhen Pang; Long Zhao; Qihang Shang; Tinghua Meng; Liang Zhao; Liuxing Feng; Shuangjia Wang; Ping Guo; Xiurong Wu; Qin Lin; Hua Wu; Weipeng Huang; Long Sun; Haojun Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-10-15       Impact factor: 9.236

3.  Combined [68 Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy.

Authors:  Ian Alberts; Robin Schepers; Konstantinos Zeimpekis; Hasan Sari; Axel Rominger; Ali Afshar-Oromieh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-09-22       Impact factor: 10.057

4.  Ga-68-PSMA-11 PET/CT in Patients with Biochemical Recurrence of Prostate Cancer after Primary Treatment with Curative Intent-Impact of Delayed Imaging.

Authors:  Jolanta Kunikowska; Kacper Pełka; Omar Tayara; Leszek Królicki
Journal:  J Clin Med       Date:  2022-06-09       Impact factor: 4.964

5.  Use of 68Ga-PSMA-11 and 18F-FDG PET-CT Dual-Tracer to Differentiate Between Lymph Node Metastases and Ganglia.

Authors:  Yiping Shi; Lian Xu; Yinjie Zhu; Yining Wang; Ruohua Chen; Jianjun Liu
Journal:  Front Oncol       Date:  2021-03-10       Impact factor: 6.244

6.  The Heterogeneous Metabolic Patterns of Ganglia in 68Ga-PSMA, 11C-choline, and 18F-FDG PET/CT in Prostate Cancer Patients.

Authors:  Yiping Shi; Jian Guo Wu; Lian Xu; Yinjie Zhu; Yining Wang; Gan Huang; Jianjun Liu; Ruohua Chen
Journal:  Front Oncol       Date:  2021-04-23       Impact factor: 6.244

7.  Abbreviated scan protocols to capture 18F-FDG kinetics for long axial FOV PET scanners.

Authors:  Varsha Viswanath; Hasan Sari; Austin R Pantel; Maurizio Conti; Margaret E Daube-Witherspoon; Clemens Mingels; Ian Alberts; Lars Eriksson; Kuangyu Shi; Axel Rominger; Joel S Karp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-12       Impact factor: 10.057

8.  Intra-patient comparison of physiologic 68Ga-PSMA-11 and 18F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay.

Authors:  Medhat M Osman; Amir Iravani; Michael S Hofman; Rodney J Hicks
Journal:  Cancer Imaging       Date:  2021-04-16       Impact factor: 3.909

9.  The influence of digital PET/CT on diagnostic certainty and interrater reliability in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer.

Authors:  Ian Alberts; Jan-Niklas Hünermund; Christos Sachpekidis; Clemens Mingels; Viktor Fech; Karl Peter Bohn; Axel Rominger; Ali Afshar-Oromieh
Journal:  Eur Radiol       Date:  2021-04-15       Impact factor: 5.315

10.  Feasibility of late acquisition [68Ga]Ga-PSMA-11 PET/CT using a long axial field-of-view PET/CT scanner for the diagnosis of recurrent prostate cancer-first clinical experiences.

Authors:  Ian Alberts; George Prenosil; Clemens Mingels; Karl Peter Bohn; Marco Viscione; Hasan Sari; Axel Rominger; Ali Afshar-Oromieh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-21       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.